Villanueva V, et al. - In patients with focal epilepsy, researchers assessed long-term efficacy and tolerability of brivaracetam. From November 2016 to June 2017, patients (aged ≥16 years) were started on brivaracetam and followed over 1 year. Data were collected from medical records at 3, 6, and 12 months after initiation of treatment for safety- and seizure-related outcomes assessment. The analysis included 575 patients (most treated with ≥4 lifetime antiepileptic drugs). According to this multicenter retrospective study, brivaracetam was efficacious and well-tolerated in a large population of patients with predominantly drug-resistant epilepsy. There were no unexpected adverse events (AEs) over 1 year and the incidence of psychiatric AEs (PAEs) was lower than that of levetiracetam. The most frequently reported AEs were somnolence, irritability and dizziness. In patients aged ≥65 years, seizure-freedom was attained by 37.5%.